ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1171

Differences in Microbiome Profiles Based on Pain Severity and Inflammatory Biomarkers in Acute Low Back Pain

Rebecca Fillipo1, Michael Brown2, Jason Arnold2, Colleen Burke3, Stephanie Danyluk2, Kelley Seebeck2 and Adam Goode2, 1Duke University School of Medicine, Durham, NC, 2Duke University, Durham, NC, 3Duke University School of Medicine, Chapel Hill, NC

Meeting: ACR Convergence 2024

Keywords: Back pain, immunology, Inflammation, microbiome

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 17, 2024

Title: Orthopedics, Low Back Pain, & Rehabilitation – ACR/ARP Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Low Back Pain (LBP) is highly prevalent, with up to 25% of individuals experiencing LBP each year, with as many as 32% transitioning to chronic LBP. Microbiome (MB) profiles, including the ratio of Prevotella to Bacteroides, can influence systemic inflammation, potentially affecting pain perception. Examining MB and immunological profiles in acute LBP may elucidate mechanisms contributing to risk of chronic LBP. The purpose of this study was to determine if MB profiles differed based on pain severity,  immune cell status and functionality, and inflammatory biomarkers in individuals with acute LBP.

Methods: Community-based participants with acute LBP (pain < 4 weeks with no pain in the prior 30 days), were recruited.. At the baseline visit, pain questionnaires and blood samples were collected. Participants were asked to collect and return a fecal sample within 1 week of their baseline visit. Participants were classified into acute LBP impact categories with more frequent (most or everyday) and intense (>30 / 100 self-reported) LBP considered high impact. Illumina amplicon sequencing of the 4th variable region of the 16S rRNA was performed on fecal microbiome samples, and plasma cytokine analysis was completed to measure Tumor Necrosis Factor (TNF) levels, a proinflammatory cytokine secreted by immune cells. MB profiles were compared using nonparametric methods based on LBP impact (high vs low) and relative TNF levels (high vs low, based on the sample median). Peripheral blood mononuclear cell (PBMC) phenotyping and stimulation assays were used to test the association between innate and adaptive immune status versus the relative abundance of bacteria using parametric methods.

Results: N=19 participants (mean age 49.3 years [range 24-74], 58% identified as Non-Hispanic White) completed a baseline visit and returned fecal MB samples. Seven participants were classified as having high impact acute LBP, indicating more frequent and more severe pain. A non-significant trend of higher relative abundance of Prevotella in participants with high-impact acute LBP was found (mean 0.215 vs 0.153; W=51.5, p=0.44) (Figure 1A). In participants with higher plasma TNF levels, trends of higher abundance of Prevotella (mean 0.213 vs 0.135; W = 48, p = 0.50) and lower abundance of Bacteroides (mean 0.137 vs 0.216; W=25, p=0.20) were found (Figure 1B). In PBMC (n=17), Prevotella and Bacteroides load was significantly associated with gd T cells, CD16+ monocytes (Figure 2), and LPS-mediated induction of the pro-inflammatory cytokine IL-12 (Figure 3).

Conclusion: Microbiome profiles may differ in individuals with acute LBP based on inflammatory status and severity of LBP, though larger sample sizes are needed. Understanding differences in MB profiles may lead to alternative treatment options and early identification of individuals at risk for poor long-term prognosis for LBP.

Supporting image 1

Figure 1. Differences in Prevotella and Bacteroides in participants based on acute LBP impact (A) and inflammatory signaling with tissue necrosis factor (TNF) (B).

Supporting image 2

Figure 2. Features tested by flow cytometry stratified by Bacteroides and Prevotella genus frequencies in stool microbiome (A) or by LBP impact measured at baseline (B). Mean -/+ SEM are shown; p-values are from unpaired t-test, n=17 samples with matching flow cytometry and microbiome information.

Supporting image 3

Assay for microbiome pilot cohort (n=17) stratified by median Prevotella (Prev) or Bacteroides (Bacter) load. (*) Significant unpaired t-test (p<0.025, Bonferroni adjusted); log (Fold Mock) is shown.


Disclosures: R. Fillipo: None; M. Brown: None; J. Arnold: None; C. Burke: None; S. Danyluk: None; K. Seebeck: None; A. Goode: None.

To cite this abstract in AMA style:

Fillipo R, Brown M, Arnold J, Burke C, Danyluk S, Seebeck K, Goode A. Differences in Microbiome Profiles Based on Pain Severity and Inflammatory Biomarkers in Acute Low Back Pain [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/differences-in-microbiome-profiles-based-on-pain-severity-and-inflammatory-biomarkers-in-acute-low-back-pain/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differences-in-microbiome-profiles-based-on-pain-severity-and-inflammatory-biomarkers-in-acute-low-back-pain/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology